Skip to main content
    S

    Spero Therapeutics Inc (SPRO)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.95
    -0.05 (-5.35%)

    Market Cap: $58.26M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Spero Therapeutics Inc (SPRO) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Spero Therapeutics (SPRO) to earn -$0.58 per share in the fiscal year ending Dec 31, 2026, on revenue of $258000. Of 3 analysts, 2 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. For the fiscal year ending Dec 31, 2027, the EPS consensus is -$0.11.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 3 ratings average 2.33, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 67% of the ratings.

    RatingAnalystsShare
    Strong Buy00.0%
    Buy266.7%
    Hold133.3%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    3

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a smaller loss.

    Fiscal year ending Dec 31, 2026
    -$0.58
    EPS consensus, revenue $258000
    Fiscal year ending Dec 31, 2027
    -$0.11
    EPS consensus
    Next report
    Mar 24, 2027
    Estimated

    EPS range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.58-$0.58 to -$0.581$258000$258000 to $2580001
    Dec 31, 2027-$0.11-$0.88 to $0.672N/AN/A1

    Quarterly Estimates

    The EPS consensus rises from -$0.21 for the quarter ending Dec 31, 2026 to -$0.14 for the quarter ending Mar 31, 2027.

    EPS range

    Quarter endingEPS consensusEPS rangeEPS analysts
    Dec 31, 2026-$0.21-$0.26 to -$0.154
    Mar 31, 2027-$0.14-$0.14 to -$0.141

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 2 upward and 0 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202600
    Fiscal year ending Dec 31, 202710
    Quarter ending Mar 31, 202710

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has turned from a profit of $0.67 to a loss.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$0.58-$0.29-$0.29-$0.29$0.67N/A
    Fiscal year ending Dec 31, 2027-$0.11$0.67$0.67$0.67$0.76N/A

    Frequently Asked Questions About SPRO

    What is the SPRO stock forecast?

    Consensus analyst estimates put Spero Therapeutics's EPS at -$0.58 for the fiscal year ending Dec 31, 2026, on revenue of $258000. The consensus rating from 3 analysts is Buy.

    How do analysts rate SPRO stock?

    Of 3 analysts covering Spero Therapeutics, 0 rate it Strong Buy, 2 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from SPRO next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.58, with estimates from -$0.58 to -$0.58 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.11, with estimates from -$0.88 to $0.67 from 2 analysts.

    What revenue do analysts expect from Spero Therapeutics next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $258000, with estimates from $258000 to $258000.

    How many analysts cover SPRO?

    3 analysts rate Spero Therapeutics stock, and 1 analyst estimates its EPS for the fiscal year ending Dec 31, 2026.